首页 产品目录 分子砌块 按官能团 醇类 5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide

5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide

5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量
1mg 95% 询价
- +
5mg 95% 询价
- +
10mg 95% 询价
- +
25mg 95% 询价
- +
50mg 95% 询价
- +
100mg 95% 询价
- +
晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

186392-40-5

英文名称

5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide

别名

CS-231;[R-(R*,S*)]-5-Chloro-N-[3-(diMethylaMino)-2-hydroxy-3-oxo- 1-(phenylMethyl)propyl]-1H-indole-2-carboxaMide;5-Chloro-N-[(1S,2R)-3-(diMethylaMino)-2-hydroxy-3-oxo-1-(phenylMethyl)propyl]-1H-indole-2-carboxaMide;CP 91149;5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide;CP 91149 USP/EP/BP;CP-91149 CP91149;CP-91149, 10 mM in DMSO

标准英文名

5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide

分子式

C21H22ClN3O3

分子量

399.88

精确分子量

399.13

SMILES

CN(C)C(=O)[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CC2=C(C=CC(Cl)=C2)N1

标准SMILES

CN(C)C(=O)[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CC2C=C(Cl)C=CC=2N1

用途

CP-91149 is a selective inhibitor of glycogen phosphorylase (GP) with an IC50 of 0.13 μM in the presence of glucose, showing 5- to 10-fold reduced potency in the absence of glucose; it exhibits potent inhibitory activity against human liver glycogen phosphorylase a (HLGPa) (200-fold more potent than caffeine, IC50 = 26 μM), human muscle phosphorylase a and b (IC50 = 0.2 μM and ~0.3 μM, respectively), and brain GP in A549 cells (IC50 = 0.5 μM); it dose-dependently inhibits glucagon-stimulated hepatic glycogenolysis in isolated rat and primary human hepatocytes (IC50 ~2.1 μM); induces inactivation of phosphorylase and concurrent activation of glycogen synthase, leading to increased glycogen synthesis (7-fold at 5 mM glucose and 2-fold at 20 mM glucose); partially counteracts the effects of GP overexpression; promotes dephosphorylation and activation of glycogen synthase (GS) in non-engineered or GP-overexpressing human muscle cells, but only in glycogen-depleted cells; causes significant glycogen accumulation in A549 and HSF55 cells at 10–30 μM; increases G1-phase cell population with a concomitant decrease in S-phase cells in HSF55 cells, correlating with upregulated p21 and p27 expression; lowers blood glucose by 100–120 mg/dL in diabetic ob/ob mice following oral administration (25–50 mg/kg) via inhibition of hepatic glycogenolysis without inducing hypoglycemia; does not reduce blood glucose in normoglycemic, non-diabetic mice; and, when co-administered with CS-917, enhances the suppression of hepatic glycogenolysis and achieves greater glucose-lowering effects than CS-917 alone in non-fasted Goto-Kakizaki (GK) rats.

InChIKey

HINJNZFCMLSBCI-PKOBYXMFSA-N

安全信息

SureRoute逆合成路线

1.  186392-40-5 逆合成路线 1

—
—
—
—
ACGBLJ738
186392-40-5
来源: SureRoute

2.  186392-40-5 逆合成路线 2

—
—
ACJTHW053
10517-21-2
ACGBLJ738
186392-40-5
来源: SureRoute

3.  186392-40-5 逆合成路线 3

—
—
—
—
ACGBLJ738
186392-40-5
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手